This expert perspective includes recommended communication strategies—and some examples—for how states can elevate coverage options and help ensure that more residents can access health insurance during these uncertain times.
Substance Use Disorder (SUD) and Mental Health
|If you have materials you are willing to share with other states through this page, or if there are topics of particular concern that you would like addressed, please contact SHVS.|
STATE HEALTH AND VALUE STRATEGIES RESOURCES
SHVS/Manatt Health. State Medicaid and CHIP Strategies to Respond to the COVID-19 Public Health Crisis This expert perspective, written by experts at Manatt Health, discusses strategies state Medicaid and CHIP agencies can pursue as part of their response to COVID-19.
SHVS/Manatt Health. Responding to COVID-19: State Strategies for Medicaid and Commercial Health Insurance Oversight Webinar recording and slide deck from webinar hosted on March 18, 2020.
STATE TEMPLATES AND TOOLKITS
CMS. 1115 Application Process This page includes guidance and a template for COVID-19 1115 waiver demonstrations.
FEDERAL STATUTE AND GUIDANCE
CMS/CMCS. COVID-19 Frequently Asked Questions (FAQs) for State Medicaid and Children’s Health Insurance Program (CHIP) Agencies These updated FAQs for state Medicaid and CHIP agencies address available resources for emergency preparedness and response efforts, and flexibilities related to eligibility and enrollment, benefits, cost-sharing, financing, and workforce.
Substance Abuse and Mental health Services Administration (SAMHSA). Considerations for Crisis Centers and Clinicians in Managing the Treatment of Alcohol or Benzodiazepine Withdrawal during the COVID-19 Epidemic
Substance Abuse and Mental health Services Administration (SAMHSA). Considerations for the Care and Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic This guidance advises outpatient providers to utilize telehealth, whenever possible, reschedule non-urgent appointments, reach out to high risk patients for COVID-19, eliminate cancellation/no show fees.
Substance Abuse and Mental health Services Administration (SAMHSA). Frequently Asked Questions (FAQs) Related to COVID-19 for SAMHSA Grant Recipients This FAQ addresses general questions associated with award and management of SAMHSA discretionary grants that may arise in relation to COVID-19.
Substance Abuse and Mental health Services Administration (SAMHSA). Interim Considerations for State Psychiatric Hospitals This guidance details infection control and social distancing recommendations for state psychiatric hospitals.
Substance Abuse and Mental health Services Administration (SAMHSA). OTP Guidance for Patients Quarantined at Home with the Coronavirus This guidance advises that Opioid Treatment Programs on providing medications to patients who are quarantined with COVID-19.
Substance Abuse and Mental health Services Administration (SAMHSA). COVID-19 Public Health Emergency Response and 42 CFR Part 2 Guidance This guidance clarifies that medical emergency exception to Part 2 applies during COVID-19.
Substance Abuse and Mental health Services Administration (SAMHSA). Opioid Treatment Program (OTP) Guidance
Drug Enforcement Administration (DEA). Exception to Regulations Emergency Oral CII Prescription This guidance allows prescribers and practitoners to issue time limited prescriptions of schedule II drugs via oral communication (e.g., telephone) under limited circumstances.
Drug Enforcement Administration (DEA). Exception to Separate Registration Requirements Across State Lines This guidance allows practitioners to dispense schedule II-IV drugs (including methadone, buprenorphine and opioids) not only in their home states but also in states with which their home stateshave reciprocity.
Drug Enforcement Administration (DEA). Exemption Allowing Alternate Delivery Methods for OTPs This guidance allows OTPs to make “door stop” deliveries for medications for opioid use disorder in a lock-box for patients under quarantine.
Drug Enforcement Administration (DEA). Registrant Guidance on Controlled Substance Prescription Refills This guidance allows pharmacists to dispense early refills of prescriptions for schedule II-IV drugs (including methadone, buprenorphine and opioids) consistent with state law and regulation.
Substance Abuse and Mental health Services Administration (SAMHSA). FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency This FAQ clarifies that OTPs may initiate new patients on buprenorphine via telehealth and without an in-person visit, but maintains the face to face requirement for initiation with methadone.
Foundation for Opioid Response Efforts (FORE), National Academy for State Health Policy (NASHP), Manatt Health Federal and State Policy Levers to Maintain Access to Medications for Opioid Use Disorder During the COVID-19 Pandemic
STATE EXAMPLES AND MODELS
California. DHCS COVID‑19 Response CA developed a robust, centralized COVID-19 resource page that provides guidance related to providers, HCBS, and federal requests/waivers.